The FDA just voted on BPC-157, TB-500 and 5 other peptides. Here's what actually happened.
On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted on whether seven peptides should be added to the Section 503A Bulk Drug Substances List. We break down every vote count, what the committee actually recommended, and — just as important — what a "yes" vote does not mean yet.
How the PCAC voted, peptide by peptide
The committee took each nomination separately, voting on the free-base and acetate forms of each substance. FDA staff had recommended against all seven; the committee's final votes broke from that recommendation on six of them.
Peptide Care Network: Patient Connection Program
A separate, transparent patient inquiry service designed for clinics and healthcare providers seeking to connect with individuals interested in peptide-based protocols.
How It Works
If you're interested in connecting with clinics that specialize in peptide protocols, complete the form on the right. Your information—including which peptides interest you most—will be provided to vetted healthcare providers in your region seeking qualified patients.
Program Details
Your Data Will Be Shared
By submitting this form, you explicitly consent to having your name, email, phone (if provided), region, and peptide interests shared with and sold to licensed healthcare clinics participating in the Peptide Care Network program.
Clinic Partners
Clinics that purchase your contact information may reach out to you regarding peptide protocols, consultations, and treatment options. Not all clinics will contact you, and frequency of contact varies by clinic.
Your Rights
- Opt-out: You may unsubscribe from clinic communications at any time by replying "STOP" to any message or contacting us directly.
- Privacy: Your data will not be sold to non-medical, non-healthcare entities.
- Compliance: All clinic partners operate under healthcare privacy and marketing regulations (CAN-SPAM, state telemarketing laws, etc.).
Not Medical Advice
This is a patient connection service only. Neither BioResearch Systems nor clinic partners provide medical diagnosis or treatment through this program. Clinics will offer consultations based on your stated interests.
What actually happens next
Category 2 removal — April 23, 2026
All seven nominated peptides were removed from the FDA's restricted Category 2 list earlier in 2026, which made them eligible for PCAC review. This step did not legalize compounding on its own.
PCAC review and vote — July 23–24, 2026
The committee voted to recommend six of the seven nominated peptides for the 503A Bulks List. These are advisory recommendations to the FDA, not binding decisions.
FDA review of the recommendation
The FDA is not obligated to follow the committee's vote, though it has historically tended to. The agency will decide whether to move forward with formal rulemaking for each recommended substance.
Notice of proposed rulemaking & public comment
If the FDA proceeds, it publishes a proposed rule in the Federal Register and opens a public comment period before any substance can be finalized onto the 503A Bulks List.
Final rule
Only after a final rule is published would licensed 503A pharmacies gain a clear legal pathway to compound these substances against an individual prescription. Analysts following the docket generally expect this to extend into 2027.
Educational Insights & Regulatory Alignment
FDA Regulatory Tracking
Ongoing coverage of the PCAC's docket, the FDA's rulemaking timeline, and what each procedural step means for 503A and 503B compounding eligibility.
Biological Product Education
Objective literature summaries for researchers, healthcare providers, and academic bodies on peptides and related biological compounds under regulatory review.
Research & Inquiry Handling
A structured intake process for questions about peptide classification status, compounding legality, and institutional research protocols.
Common questions about the PCAC vote
The committee voted on whether seven peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon, and emideltide (DSIP) — should be recommended for the Section 503A Bulk Drug Substances List, which governs what licensed compounding pharmacies may prepare against an individual prescription.
No. The committee recommended both for the 503A Bulks List, along with KPV, MOTS-c, Semax, and Epitalon. A recommendation is advisory only — neither substance is an FDA-approved drug, and formal rulemaking still has to happen before compounding could become legal.
Not yet. The FDA still needs to complete a rulemaking process — including a proposed rule and public comment period — before any of the recommended substances are formally added to the 503A Bulks List.
Emideltide, also called DSIP (delta sleep-inducing peptide), was the only one of the seven nominations the committee voted against, on a 6–7 count with one abstention.
Use the inquiry form in the Contact section below. We route questions by category — patient/caregiver, licensed clinician, compounding pharmacy, researcher or institution, and media — and aim to respond within one to two business days.
Promoting clarity in biological science
BioResearch Systems was established to provide a transparent, educational platform amid rapid regulatory shifts surrounding biological compounds and peptides. The July 2026 PCAC vote is exactly the kind of moment where clear, sourced explanation matters more than headlines.
We operate strictly as an educational portal and inquiry interface. BioResearch Systems does not sell, compound, or distribute pharmaceutical products or research chemicals. All materials presented serve informational and regulatory-tracking purposes only and are not a substitute for advice from a licensed physician, pharmacist, or attorney.
Regulatory Compliance
Aligning all informational content strictly with FDA, 503A, and 503B administrative frameworks.
Objective Science
Evidence-based summaries on peptide biochemistry and laboratory standards, sourced from primary FDA materials.
Institutional Outreach
Assisting research institutions and clinical leaders with compliant regulatory inquiries.
Docket Transparency
Bridging the gap between agency advisory decisions and public scientific understanding.
General inquiry form
Have a question about the PCAC vote, the 503A rulemaking timeline, or a specific peptide's classification? Tell us who you are and what you need — we route inquiries by category so the right person follows up.